Bioprofarma Bagó is pleased to present the launch of the product TSUMIS® carfilzomib, for its Hematology Line.
TSUMIS® carfilzomib is approved by ANMAT, in combination with daratumumab and dexamethasone, lenalidomide and dexamethasone or dexamethasone alone, for the treatment of adult patients with multiple myeloma who have received at least one prior treatment.
TSUMIS® carfilzomib is available in a single form of a pack containing a 60 mg. lyophilised vial.
TSUMIS® carfilzomib joins the portfolio of products for the treatment of multiple myeloma, together with MIASOMA® bortezomib and MYELENZ® lenalidomide.
This new treatment alternative comes to give specialists more options for the care of their patients.
We invite you all to take a look at a short literature to learn more about this launch!
